Navigation Links
Ventana Introduces the BenchMark Special Stains Platform
Date:3/19/2012

TUCSON, Ariz., March 19, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, is now introducing a novel platform for special stains, built on its industry-leading VENTANA BenchMark technology.  Answering customers' challenges with their current process, the new BenchMark Special Stains platform offers walk-away automation, baking through staining including deparaffinization, random batch access, connectivity to the VANTAGE workflow solution, and the revolutionary VENTANA CareGiver(1) remote support, creating an ideal system for laboratories worldwide.

Derek Wheeler, Histology Supervisor, The Reading Hospital and Medical Center, teamed up with Ventana to ensure the full customer experience was incorporated into the new system architecture.  "The improvement to workflow with the new BenchMark Special Stains due to independent slide heating and online deparaffinization is significant.  I've seen the value special stains automation brings my laboratory by freeing up my technicians for over 10 years now. The BenchMark Special Stains platform adds a much improved level of efficiency and excellent results."    

Ventana is the industry leader(2) in the special stains instrument market, and this next level of instrument automation will dramatically enhance testing efficiency over manual processes.  WATCH this revealing demonstration of manual staining workflow vs. the new BenchMark Special Stains instrument. 

After evaluating the instrument and slides Brian Le, MD Pathologist, The Reading Hospital and Medical Center said,   "Our team is impressed with the quality and consistency of the BenchMark Special Stains slides.  The technologists and histologists are enthusiastic about how the automation enhancements have improved the workflow during the day."

In addition to offering automation, quality, and consistency, the BenchMark Special Stains platform utilizes the same dynamic software interface as the BenchMark ULTRA platform, enabling enhanced ease of use and protocol editing.  As part of maintaining VENTANA world class safety standards, the platform and reagent kits are designed to minimize exposure for lab personnel.  When you combine these features with its connectivity to other VENTANA laboratory systems and VENTANA CareGiver remote support, the BenchMark Special Stains platform is currently the most comprehensive special staining solution on the market(3).

"Ventana is all about innovation in anatomic pathology," said Mara G. Aspinall, President, Ventana Medical Systems, Inc.  "Special Stains is a critical part of the lab workflow, and the BenchMark Special Stains platform embodies our commitment to empowering our customers with the most advanced diagnostic solutions so they can deliver the highest possible standard of patient care."

(1)VENTANA CareGiver remote support delivers a comprehensive histology remote connectivity solution for VENTANA systems including the BenchMark Special Stains platform, SYMPHONY H&E stainer and BenchMark ULTRA IHC/ISH stainer.

 

(2,3)Ventana internal sales and market assessments, 2011

About Ventana Medical Systems, Inc.                              
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving personalized healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. Visit www.ventana.com to learn more.

VENTANA, the VENTANA logo, SYMPHONY, and BenchMark are trademarks of Roche.

VMSI Media Relations
Jacqueline Bucher
Director, Corporate Communications
Phone: 520-877-7288
e-mail: jacquie.bucher@ventana.roche.com

 


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ventana Receives FDA Clearance for Ki-67 (30-9) Image Analysis and Digital Read Applications
2. Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy
3. Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat
4. Ventana Medical Systems, Inc. and Advanced Cell Diagnostics Enter Worldwide Co-Promotion Agreement for Fully Automated RNA In Situ Hybridization Assay Systems
5. Ventana Medical Systems, Inc. Introduces Groundbreaking Laboratory Workflow Integration
6. Ventana Medical Systems, Inc. Unveils High-throughput Slide Scanner for Digital Pathology
7. Ventana Medical Systems, Inc. Receives FDA Approval for the First Fully Automated Diagnostic Assay for HER2 Gene Status Determination in Breast Cancer Patients
8. Ventana Medical Systems, Inc. Launches Virtuoso Software for Digital Pathology
9. CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer
10. Endologix Announces First Clinical Implant of Ventana™ Stent Graft
11. Cynosure Introduces Enhanced Elite+ and Apogee+ Workstations for Faster Aesthetic Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):